Organon & Co. Common Stock vs PPG Industries, Inc. — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while PPG Industries, Inc. trades at $104.87 (market cap $23.24B). The key difference: PPG Industries, Inc. is far larger — about 6.4× Organon & Co. Common Stock's market cap, and PPG Industries, Inc. pays the higher dividend (2.83%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and PPG Industries, Inc. for 68 Days on average.
| OGN | PPG | |
|---|---|---|
Market Cap | $3.62B | $23.24B |
Volume | 2,892,999 | 1,719,217 |
Sector | Health | Basic Materials |
52-Week High | $13.81 | $131.56 |
52-Week Low | $5.70 | $94.34 |
Typical Hold Time | 0 Days | 68 Days |
Enterprise Value | $11.04B | $29.11B |
Dividend Yield | 0.58% | 2.83% |
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
PPG Industries trades at $104.87, up 1.12% today, amid mixed technical signals and fundamental strength. The stock shows bearish technical indicators with support at $103 and resistance at $105, while fundamentals reveal solid profitability with 9.57% net margin and 19.63% ROE. Recent earnings show volatility with Q1 2026 beating expectations but Q2 2026 missing, with Q3 2026 results pending. The company maintains strong cash flow generation with $1.94B from operations in 2025 and recently announced a $0.74 dividend for H2-2026.
PPG presents a balanced risk-reward profile with analyst consensus pointing to 24% upside to the $130.50 price target. Strong fundamentals and institutional support (55% buy ratings) offset near-term technical weakness and segment-specific challenges in Automotive Refinish. Key risks include margin pressures in high-margin segments and European demand softness, while catalysts include Q3 earnings on Oct 27 and continued aerospace strength.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →